49 results about "Systolic function" patented technology

Devices and methods for therapy control based on electromechanical timing involve detecting electrical activation of a patient's heart, and detecting mechanical cardiac activity resulting from the electrical activation. A timing relationship is determined between the electrical activation and the mechanical activity. A therapy is controlled based on the timing relationship. The therapy may improve intraventricular dyssynchrony of the patient's heart, or treat at least one of diastolic and systolic dysfunction and / or dyssynchrony of the patient's heart, for example. Electrical activation may be detected by sensing delivery of an electrical stimulation pulse to the heart or sensing intrinsic depolarization of the patient's heart. Mechanical activity may be detected by sensing heart sounds, a change in one or more of left ventricular impedance, ventricular pressure, right ventricular pressure, left atrial pressure, right atrial pressure, systemic arterial pressure and pulmonary artery pressure.

A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5-40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6-12 mm Hg, during ventricular diastole of the heart.

Systems and methods for selection of electrodes and related pacing configuration parameters used to pace a heart chamber are described. A change in the hemodynamic state of a patient is detected. Responsive to the detected change, a distribution of an electrical, mechanical, or electromechanical parameter related to contractile function of a heart chamber with respect to locations of multiple electrodes disposed within the heart chamber is determined. A pacing output configuration, including one or more electrodes of the multiple electrodes, is selected and the heart chamber is paced using the selected pacing output configuration.

A heart monitoring device has a control circuit, the control circuit being adapted to be electrically connected to electrode surfaces arranged at two different positions of the heart. The control circuit derives an impedance value indicative of the impedance between the electrode surfaces. Furthermore, the control circuit is arranged to determine and monitor a relationship between a positive rate of change and a negative rate of change of the impedance value. The device can, in particular, be used to detect and treat a systolic dysfunction of a heart.

A method and apparatus for optimizing and assessing the response to extra-systolic stimulation (ESS) are provided. An optimization / monitoring parameter is calculated as a function of potentiation ratio, PR, and recirculation fraction, RF, derived from measurements of myocardial contractile function during and after ESS. PR may be computed as the ratio of the contractile function on post-extra-systolic beats during ESS to baseline contractile function. RF may be computed as the slope of a linear regression performed on a plot of the contractile function for a post-extra-systolic beat versus the contractile function for the previous post-extra-systolic beat after ESS is ceased. The ESI resulting in a maximum optimization / monitoring parameter, preferably computed as the product of PR and RF, is determined as the optimal ESI. The operating ESI may be automatically adjusted, and / or PR and RF data may be stored for monitoring purposes.

The present invention relates to one kind of heart septa defect stopper with self regulating function includes a right disc of double layer contracting metal net, and a left disc comprising two or more supporting metal rods and coating film. The film -coated disc has its support rods penetrating the meshes of the metal net disc for connection. In the connection between the two discs, there is universal joint to make the interval between the two discs capable of being altered properly, so that the connection possess self adapting function and the two discs may be attached closely to the valve with heart septa defect resulting in excellent stopping effect. The present invention can also lower the thrombosis rate and facilitate the doctorí»s operation.

Bioactive implant for myocardial regeneration and ventricular chamber support including an elastomeric microporous membrane. The elastomeric microporous membrane being at least one non-degradable polymer and at least one partially degradable polymer. The non-degradable polymer is selected from polyethylacrylate and polyethylacrylate copolymerized with a hydroxyethylacrylate comonomer. The partially degradable polymer is selected from caprolactone 2-(methacryloyloxy)ethyl ester and caprolactone 2-(methacryloyloxy)ethyl ester copolymerized with ethylacrylate. The elastomeric microporous membrane further includes a nanofiber hydrogel, and cells. The bioactive implant, having one or two helical loops, contributes to the restauration of the heart conical shape. Cardiac wrapping by ventricular support bioprostheses of the present invention, having reinforcement bands spatially distributed as helicoids, recovers the sequential contraction of the myocardium resulting in the successive shortening and lengthening of the ventricles, therefore improving the ejection (systolic function) and suction of blood (diastolic function).

The invention relates to the field of cryoablation, in particular to a cryoablation duct. The cryoablation duct comprises a far end duct body, a melt saccule and a mapping saccule, wherein the far endduct body is a far end segment of the entire duct body of a cryoablation duct; the melt saccule is mounted at the end of the far end duct body, and is used for cryoablation; the mapping saccule has functions of expanding and contraction, and a plurality of mapping electrodes are arranged on the surface of the mapping saccule; and the mapping saccule is detachably arranged in the far end tube bodyor the melt saccule. During operation, the mapping saccule extends out from the front end of the melt saccule. The invention aims to provide the cryoablation duct which can increase the mapping effect on mapping in frozen saccule melt of the heart.

The invention discloses a drug novel use of fucoidan polysaccharide sulfate. The use is the application of the fucoidan polysaccharide sulfate in preparing the following products: (1), a product for preventing and / or treating diabetic cardiomyopathy; (2), a product for inhibiting diabetic myocardial oxidative stress; and (3), a product for inhibiting expression and activation of PKC (Protein Kinase C) beta in diabetic cardiomyopathy; and (4), a product for relieving cardiac interstitial fibrosis of a diabetic. The fucoidan polysaccharide sulfate is preferably LMWF (Fucoidan Polysaccharide Sulfate) with weight-average molecular weight of 3-30KD. According to the pharmacodynamic experiment, the LMWF can be used for generating beneficial interference to the development of pathogenetic condition of the diabetic cardiomyopathy by strengthening the myocardial systolic function and relieving cardiac fibrosis. More importantly, the LMWF can be used for effectively inhibiting oxidative stress by regulating the activity of antioxidase, and can be used for inhibiting the expression of protein kinase C beta (PKCbeta) subtype. The LMWF is from the natural existing kelp, so that the availability and safety of the kelp are beneficial to using the fucoidan polysaccharide sulfate as a potential clinical treatment drug and preventing the diabetic cardiomyopathy.

The invention consists of a device and method for the prediction of left ventricular ejection fraction (EF) and other cardiac hemodynamic parameters using systolic time intervals in patients with narrow QRS, right bundle branch block, left bundle branch block, right ventricular and / or left ventricular cardiac pacing and in the presence of arrhythmia, such as atrial fibrillation. The device has three inputs: the ECG, a peripheral pulse and a phonocardiogram. Timing parameters are obtained from these signals to calculate a systolic function index, used for the prediction of ejection fraction. Given the invention's features it would be now possible to assess cardiac performance and specifically left ventricular ejection fraction in ambulatory patients as well as during invasive procedures such as the implant of cardiac rhythm management devices. Also, an implantable embodiment of the invention would allow constant monitoring of cardiac performance, parameter adjustment of cardiac devices and automatic drug infusion.

The invention discloses the application of CTRP3 to preparation of drugs for preventing and treating cardiac hypertrophy. A pathologic hypertrophy model of cells is established in the invention, and the pathologic hypertrophy model proves that administration of CTRP3 can lower the expression of cardiac hypertrophy marker molecules and reduce the average surface area of cardiac muscle cells. An in-vivo animal model is also established in the invention, and the in-vivo animal model proves that after administration of CTRP3, the heart-to-body ratio and the lung-to-body ratio of a mouse significantly decrease, the left ventricular systolic function of the heart of the mouse is significantly improved; interventricular septal thickness in a systolic period and left ventricular posterior wall thickness in a diastolic period are significantly reduced; the cross-sectional areas of myocardial cells significantly decrease; the myocardial cells are arranged more closely and regularly; the degreesof myocardial tissue interstitial fibrosis and pericapillary fibrosis are greatly lowered; and thus, it is indicated that CTRP3 has significant prevention effect on pathological cardiac hypertrophy, delays the occurrence of heart failures, and has good clinical application prospects.

The invention relates to the field of a drug preparation, and particularly relates to a powder injection for injection and a preparation method thereof. The powder injection for injection comprises a compound shown in the formula I and a freeze-drying protective additive, wherein the weight ratio of the compound shown in the formula I to the freeze-drying protective additive is (20-50): (100-250). The powder injection for injection provided by the invention is stable in quality, and high in treatment safety, and can be used for effectively treating deterioration of heart failure with a decreased left ventricular systolic function; and the preparation technology of the powder injection for injection is simple and convenient, controllable, and suitable for industrial production.

The invention relates to the field of a drug preparation, and particularly relates to a powder injection for injection and a preparation method thereof. The powder injection for injection comprises a compound shown in the formula I and a freeze-drying protective additive, wherein the weight ratio of the compound shown in the formula I to the freeze-drying protective additive is (20-50): (100-250). The powder injection for injection provided by the invention is stable in quality, and high in treatment safety, and can be used for effectively treating deterioration of heart failure with a decreased left ventricular systolic function; and the preparation technology of the powder injection for injection is simple and convenient, controllable, and suitable for industrial production.

The present invention pertains to the field of biotechnology and medicine and discloses a usage of Heat Shock Protein 27(HSP27) in the heart protection aspect. The present invention firstly reveals that the HSP27 gene can be applied in the specific myofilament protein for stabilizing ischemia, heart failure and other damages of the heart muscle, so as to improve the contractile function of the heart muscle; the present invention also proves that the HSP27 transfected by the adenovirus vector can improve the contractile function of the heart with ischemia and can provide an effective new target for the treatment of heart diseases.

The invention discloses a novel target spot for the treatment of pulmonary arterial hypertension. The novel target spot for the treatment of pulmonary arterial hypertension aims at a serotonin 2B receptor (5-HT2BR); pulmonary arterial hypertension has a significant characteristic of high shrinkage in pulmonary artery; and inhibition on activity of the 5-HT2BR can significantly inhibit the systolic function of the pulmonary artery. The receptor can be used as a novel target spot for the treatment of pulmonary hypertension therapy.

The invention provides a traditional Chinese medicine preparation for curing benign prostatic hyperplasia. Active ingredients of the preparation are prepared from the following raw materials according to weight ratio: 10-15 of radix glehniae, 9-12 of caesalpinia, 10-15 of light red Tuckahoe, 10-15 of root of common peony, 3-6 of radix glycyrrhizae preparata, 10-20 of raw rehmannia, 5-10 of plantain seed, 10-15 of liriope, 3-10 of inula lineariifolia turcz, 6-15 of cortex lycii radicis, and 10-15 of grilled astragalus. The dosage form of the prepared medicine is one of oral liquid, capsule, troche, pill and powder. The preparation disclosed by the invention not only can be used for tonifying Qi, clearing away the heart-fire, circulating heart and kidney, smoothing kidney water, enhancing bladder systolic function, promoting reduced volume of prostate and effectively relieving bladder outlet obstruction symptoms, but also can be used for coordinating balanced action on human blood and physiological function of the five internal organs (a heart, a liver, a spleen, lungs and kidneys), conditioning qi activity and achieving the purposes of treating disease from the root; furthermore, the preparation has the advantages of being light in dosage, accurate in curative effect, short in treatment course, high in cure rate, low in operation curing probability, low in side effect, and the like.

Bioactive implant for myocardial regeneration and ventricular chamber support including an elastomeric microporous membrane. The elastomeric microporous membrane being at least one non-degradable polymer and at least one partially degradable polymer. The non-degradable polymer is selected from polyethylacrylate and polyethylacrylate copolymerized with a hydroxyethylacrylate comonomer. The partially degradable polymer is selected from caprolactone 2-(methacryloyloxy)ethyl ester and caprolactone 2-(methacryloyloxy)ethyl ester copolymerized with ethylacrylate. The elastomeric microporous membrane further includes a nanofiber hydrogel, and cells. The bioactive implant, having one or two helical loops, contributes to the restauration of the heart conical shape. Cardiac wrapping by ventricular support bioprostheses of the present invention, having reinforcement bands spatially distributed as helicoids, recovers the sequential contraction of the myocardium resulting in the successive shortening and lengthening of the ventricles, therefore improving the ejection (systolic function) and suction of blood (diastolic function).

The invention discloses an application of a Chinese medicine composition to the preparation of a medicine for treating metabolic syndrome. Tests prove that the Chinese medicine composition has effects of reducing the blood sugar of the metabolic syndrome, regulating the blood fat, improving the impaired glucose tolerance and the like, and can also decrease the left ventricular end systolic volume, improve the systolic function of the heart and reduce the thickens of the carotid wall; moreover, while improving the heart function of the patient suffered from the metabolic syndrome, the invention can obviously improve the blood vessel function of the patient suffered from the metabolic syndrome, and has the effect of treating the metabolic syndrome.

The invention discloses a medicine for treating heart qi deficiency, blood stasis and edema syndromes of chronic cardiac failure and a preparation method of the medicine. The medicine is prepared such medicinal raw materials as astragali radix, roasted rhizoma atractylodis macrocephalae, dried ginger, prepared leech, roasted semen plantaginis, poria cocos, roasted fructus aurantii immaturus, roasted semen lepidii and raw liquorice. The medicine has the beneficial effects that compared with internationally recognized treatment by use of Western medicines hydrochlorothiazide and acertil, sugar-free granules, which are developed based on the traditional Chinese medicine theory of correlation between heart and spleen, according to the treatment rules of warning heart and spleen, promoting circulation of fluid and expelling stasis and by use of a class 6 new traditional Chinese medicine preparation process, are capable of obviously improving the LVEF (Left Ventricular Ejection Fraction) and the LVFS (Left Ventricular Fractional Shortening) of chronic cardiac failure suffering rats, and therefore, the whole and radius contraction functions of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes can be obviously improved; the medicine has the trend of improving the load of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes by reducing the BNP (Brain Natriuretic Peptide) blood concentration, and therefore, the diastolic function of the left ventricles of the rats having the heart qi deficiency, blood stasis and edema syndromes can be improved. The medicine has the advantages of remarkable curative effect, no toxic and side effects and the like.

The invention relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating migraine. The invention is characterized in that the traditional Chinese medicine composition comprises the following raw material herbs: 10-15 g of rhizoma gastrodiae, 10-15 g of rhizoma pinellinae praeparata, 10-15 g of poria cocos, 3-5 g of rhizoma arisaematis, 5-8 g of scorpio, 10-12 g of bombyx batryticatus, 5-8 g of amber, 10-12 g of tangerine peel, 8-10 g of polygala tenuifolia, 10-15 g of salvia, 10-15 g of radix ophiopogonis, 5-8 g of cassia twig, 8-10 g of kudzu roots, 10-15 g of radix curcumae, and 5-10 g of radix angelicae. The raw material herbs of the invention can be added with various routine auxiliary materials and additives required by preparation of different dosage forms; routine methods of traditional Chinese medicine preparations are adopted to prepare routine dosage forms. The traditional Chinese medicine composition has the functions of activating blood and dissolving stasis, moving qi and relieving pain, inhibiting cerebral cortex and regulating blood vessel diastolic and systolic functions, can stabilize emotion and adjust insomnia, can reach the efficacy of rapidly relieving migraine, and simultaneous treatment of principal and subordinate symptoms.

An artistic flower with automatic closing and automatic shrinking functions. It installs and fixes the flower stem on the base of the flower plate, installs the flower core leaves on the flower stem, installs the electromagnet on the upper end of the flower stem, and installs the flower core on the electromagnet. Around the flower disc, the petals are installed on the flower core, and the magnetic coating is coated on the petals. The magnetic coating has electromagnetic properties. The battery and the current regulation module are installed in the inner space of the flower disc base, and the switch is installed outside the flower disc base. Connect the cables, The current regulating module, the electromagnet and the switch are connected and fixed.

The invention discloses a construction method and application of a dilated cardiomyopathy mouse model. The dilated cardiomyopathy model mouse can be constructed by a method for specifically knocking out the Prmt5 gene in myocardial cells of the mouse. The mouse with cardiac muscle cell specificity Prmt5 deletion has pathological characteristics of dilated cardiomyopathy (DCM), including thinning of heart ventricular wall, cardiac cavity dilation, myocardial fibrosis, systolic function impairment and rising of pathological marker gene expression, which finally causes death of the mouse. The mouse DCM model constructed by the method can be applied to research on development or screening of dilated cardiomyopathy drugs.

The invention relates to a composition for specifically inhibiting the expression of miR-27b and medicines containing the composition. The composition has the nucleotide sequence 5' -GCAGAACUUAGCCACUGUGAA-3' of functional molecules produced in vivo. The inhibition of the expression of miR-27b in vivo can alleviate cardiac hypertrophy and heart damage caused by stress load. The invention determines the functions of miR-27b in cardiac hypertrophy through myocardial cell experiments. A mouse model of cardiac hypertrophy caused by TAC surgically created stress load is treated by packaging adenovirus for the specific inhibition of the expression of miR-27b and synthesizing an inhibitor against miR-27b, which brings out that cardiac hypertrophy and fibrosis caused by TAC operation can be alleviated effectively by respectively utilizing two inhibitors to treat the TAC postoperative mouse, with obvious thinning of ventricular wall thickness and obvious remission of systolic function of heart.

The invention consists of a device and method for the prediction of left ventricular ejection fraction (EF) and other cardiac hemodynamic parameters using systolic time intervals in patients with narrow QRS, right bundle branch block, left bundle branch block, right ventricular and / or left ventricular cardiac pacing and in the presence of arrhythmia, such as atrial fibrillation. The device has three inputs: the ECG, a peripheral pulse and a phonocardiogram. Timing parameters are obtained from these signals to calculate a systolic function index, used for the prediction of ejection fraction. Given the invention's features it would be now possible to assess cardiac performance and specifically left ventricular ejection fraction in ambulatory patients as well as during invasive procedures such as the implant of cardiac rhythm management devices. Also, an implantable embodiment of the invention would allow constant monitoring of cardiac performance, parameter adjustment of cardiac devices and automatic drug infusion.

The invention belongs to the field of medicines, and particularly relates to a production method of an acute exacerbation chronic heart failure animal model. The acute exacerbation chronic heart failure model is built according to double factors of a clinical cause and a clinical inducement, on one hand, the acute exacerbation chronic heart failure model has the cause of a pathological disease basis myocardial infarction of chronic heart failure, and on the other hand, the acute exacerbation chronic heart failure model has the inducement of a body fluid load on the basis of the cause. The model shows two major characteristics of heart failure exacerbation after being produced successfully, wherein the two major characteristics refer to further reduction of a systolic function on the basisthat the systolic function is already weakened, and respiration function index change similar to clinical symptoms. The model can be used for studies of effectiveness of a novel medicine, the action mechanism of the novel medicine and the like.

Systems and methods for selection of electrodes and related pacing configuration parameters used to pace a heart chamber are described. A change in the hemodynamic state of a patient is detected. Responsive to the detected change, a distribution of an electrical, mechanical, or electromechanical parameter related to contractile function of a heart chamber with respect to locations of multiple electrodes disposed within the heart chamber is determined. A pacing output configuration, including one or more electrodes of the multiple electrodes, is selected and the heart chamber is paced using the selected pacing output configuration.

The invention discloses an application of Asprosin for preparing drugs for treating the ischemic heart disease. By an in-vivo animal ischemia reperfusion model, an inventor proves that after myocardial ischemia, Asprosin protein is given, so that the myocardium cell apoptosiscan be reduced, the infarct area can be reduced, and the left ventricular systolic function of the mouse heart can be improved. The Asprosin has the effect of treating the ischemic injury of the heart and has good clinical application prospect.